Skip to main content
Erschienen in: Pathology & Oncology Research 2/2020

12.03.2019 | Original Article

microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma

verfasst von: Gabriela Molinari Roberto, Regia Caroline Lira, Lara Elis Delsin, Gabriela Maciel Vieira, Marcela Oliveira Silva, Rodrigo Guedes Hakime, Mauricio Eiji Yamashita, Edgard Eduard Engel, Carlos Alberto Scrideli, Luiz Gonzaga Tone, María Sol Brassesco

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor with two peaks of incidence, in early adolescence and the elderly. Patients affected with this malignancy often present metastatic disease at diagnosis, and despite multimodality therapy, survival has not improved substantially over the past 3 decades. Recently, miR-138-5p, proposed as a crucial intracellular mediator of invasion, has been recognized to target the Rho-associated coiled-coil containing protein kinase 2 (ROCK2). Dysregulation of ROCK1 and ROCK2 was also described in OS, being associated to higher metastasis incidence and worse prognosis. Nonetheless, the specific roles of miR-138-5p in pediatric and young adult OS and its ability to modulate these kinases remain to be established. Thus, in the present study, the expression levels miR-138-5p were evaluated in a consecutive cohort of exclusively pediatric and young adult primary OS samples. In contrast to previous reports that included adult tissues, our results showed upregulation of miR-138-5p associated with reduced event-free survival and relapsed cases. In parallel, ROCK1 mRNA levels were significantly reduced in tumor samples and negatively correlated with miR-138-5p. Similar correlations were observed after studying the profiles of ROCK1 and ROCK2 by immunohistochemistry. Our data present miR-138-5p as a consistent prognostic factor in pediatric and young adult OS, reinforcing its participation in the post-transcriptional regulation of ROCK kinases.
Literatur
1.
Zurück zum Zitat Benjamin RS (2015) Osteosarcoma: better treatment through better trial design. Lancet Oncol 16(1):12–13PubMedCrossRef Benjamin RS (2015) Osteosarcoma: better treatment through better trial design. Lancet Oncol 16(1):12–13PubMedCrossRef
2.
3.
Zurück zum Zitat Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115:1531–1543PubMedCrossRef Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115:1531–1543PubMedCrossRef
5.
Zurück zum Zitat Harting MT, Blakely ML (2006) Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg 15:25–29PubMedCrossRef Harting MT, Blakely ML (2006) Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg 15:25–29PubMedCrossRef
6.
Zurück zum Zitat Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33:3029–3035PubMedPubMedCentralCrossRef Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33:3029–3035PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z (2011) ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 29:1259–1266PubMedCrossRef Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z (2011) ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 29:1259–1266PubMedCrossRef
9.
10.
Zurück zum Zitat Fusella F, Ferretti R, Recupero D, Rocca S, Di Savino A, Tornillo G, Silengo L, Turco E, Cabodi S, Provero P, Pandolfi PP, Sapino A, Tarone G, Brancaccio M (2014) Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol 234(2):152–163PubMed Fusella F, Ferretti R, Recupero D, Rocca S, Di Savino A, Tornillo G, Silengo L, Turco E, Cabodi S, Provero P, Pandolfi PP, Sapino A, Tarone G, Brancaccio M (2014) Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol 234(2):152–163PubMed
11.
Zurück zum Zitat Lochhead PA, Wickman G, Mezna M, Olson MF (2010) Activating ROCK1 somatic mutations in human cancer. Oncogene 29:2591–2598PubMedCrossRef Lochhead PA, Wickman G, Mezna M, Olson MF (2010) Activating ROCK1 somatic mutations in human cancer. Oncogene 29:2591–2598PubMedCrossRef
12.
Zurück zum Zitat Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini P-L, Cenacchi G, Picci P, Valvassori L, Scotlandi K (2014) CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene 33:1912–1921PubMedCrossRef Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini P-L, Cenacchi G, Picci P, Valvassori L, Scotlandi K (2014) CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene 33:1912–1921PubMedCrossRef
13.
Zurück zum Zitat Tan Y, Hu H, Tan W, Jin L, Liu J, Zhou H (2016) MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. Mol Med Rep 14:4422–4428PubMedCrossRef Tan Y, Hu H, Tan W, Jin L, Liu J, Zhou H (2016) MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. Mol Med Rep 14:4422–4428PubMedCrossRef
14.
Zurück zum Zitat Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q, Li L (2016) MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother 77:135–141PubMedCrossRef Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q, Li L (2016) MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother 77:135–141PubMedCrossRef
15.
Zurück zum Zitat Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, Shi F, Zhou X (2010) Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 127:505–512PubMedPubMedCentralCrossRef Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, Shi F, Zhou X (2010) Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 127:505–512PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef
17.
Zurück zum Zitat Varghese F, Bukhari AB, Malhotra R, De A (2014) IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 9:e96801PubMedPubMedCentralCrossRef Varghese F, Bukhari AB, Malhotra R, De A (2014) IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 9:e96801PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Li B, Yang X-X, Wang D, Ji H-K (2016) MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. Eur Rev Med Pharmacol Sci 20:1109–1114PubMed Li B, Yang X-X, Wang D, Ji H-K (2016) MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. Eur Rev Med Pharmacol Sci 20:1109–1114PubMed
19.
Zurück zum Zitat Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X (2009) MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett 286:217–222PubMedPubMedCentralCrossRef Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X (2009) MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett 286:217–222PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Long L, Huang G, Zhu H, Guo Y, Liu Y, Huo J (2013) Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med 11:275PubMedPubMedCentralCrossRef Long L, Huang G, Zhu H, Guo Y, Liu Y, Huo J (2013) Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med 11:275PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N, Kato K, Komatsu H, Ikeda K, Wakabayashi G, Masuda T (2008) Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99:280–286PubMedCrossRef Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N, Kato K, Komatsu H, Ikeda K, Wakabayashi G, Masuda T (2008) Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99:280–286PubMedCrossRef
22.
Zurück zum Zitat Sun D-K, Wang J-M, Zhang P, Wang Y-Q (2015) MicroRNA-138 regulates metastatic potential of bladder Cancer through ZEB2. Cell Physiol Biochem 37:2366–2374PubMedCrossRef Sun D-K, Wang J-M, Zhang P, Wang Y-Q (2015) MicroRNA-138 regulates metastatic potential of bladder Cancer through ZEB2. Cell Physiol Biochem 37:2366–2374PubMedCrossRef
23.
Zurück zum Zitat Xiao L, Zhou H, Li X-P, Chen J, Fang C, Mao C-X, Cui J-J, Zhang W, Zhou H-H, Yin J-Y, Liu Z-Q (2016) MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. Oncotarget 7:40038–40046PubMedPubMedCentralCrossRef Xiao L, Zhou H, Li X-P, Chen J, Fang C, Mao C-X, Cui J-J, Zhang W, Zhou H-H, Yin J-Y, Liu Z-Q (2016) MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. Oncotarget 7:40038–40046PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X, Deng Y, Jiang J, Sun C (2015) MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol (Dordr) 38:173–181CrossRef Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X, Deng Y, Jiang J, Sun C (2015) MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol (Dordr) 38:173–181CrossRef
25.
Zurück zum Zitat Wang Q, Tang H, Yin S, Dong C (2013) Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 29:2046–2052PubMedCrossRef Wang Q, Tang H, Yin S, Dong C (2013) Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 29:2046–2052PubMedCrossRef
26.
Zurück zum Zitat Yeh Y-M, Chuang C-M, Chao K-C, Wang L-H (2013) MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer 133:867–878PubMedCrossRef Yeh Y-M, Chuang C-M, Chao K-C, Wang L-H (2013) MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer 133:867–878PubMedCrossRef
27.
Zurück zum Zitat Jiang B, Mu W, Wang J, Lu J, Jiang S, Li L, Xu H, Tian H (2016) MicroRNA-138 functions as a tumor suppressor in osteosarcoma by targeting differentiated embryonic chondrocyte gene 2. J Exp Clin Cancer Res 35:69PubMedPubMedCentralCrossRef Jiang B, Mu W, Wang J, Lu J, Jiang S, Li L, Xu H, Tian H (2016) MicroRNA-138 functions as a tumor suppressor in osteosarcoma by targeting differentiated embryonic chondrocyte gene 2. J Exp Clin Cancer Res 35:69PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG (2008) The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33:585–593PubMed Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG (2008) The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33:585–593PubMed
29.
Zurück zum Zitat Mertsch S, Thanos S (2014) Opposing signaling of ROCK1 and ROCK2 determines the switching of substrate specificity and the mode of migration of glioblastoma cells. Mol Neurobiol 49:900–915PubMedCrossRef Mertsch S, Thanos S (2014) Opposing signaling of ROCK1 and ROCK2 determines the switching of substrate specificity and the mode of migration of glioblastoma cells. Mol Neurobiol 49:900–915PubMedCrossRef
30.
Zurück zum Zitat Wu Y, Tang Y, Li Z, Li Z, Zhao Y, Wu Z, Su Q (2014) Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma. Asia Pac J Clin Oncol 10:e33–e39PubMedCrossRef Wu Y, Tang Y, Li Z, Li Z, Zhao Y, Wu Z, Su Q (2014) Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma. Asia Pac J Clin Oncol 10:e33–e39PubMedCrossRef
31.
Zurück zum Zitat Takeba Y, Matsumoto N, Watanabe M, Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura T, Otsubo T (2012) The rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemother Pharmacol 69:1545–1555PubMedCrossRef Takeba Y, Matsumoto N, Watanabe M, Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura T, Otsubo T (2012) The rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemother Pharmacol 69:1545–1555PubMedCrossRef
32.
Zurück zum Zitat Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu J, Shi W (2012) The rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother 66:221–227PubMedCrossRef Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu J, Shi W (2012) The rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother 66:221–227PubMedCrossRef
33.
Zurück zum Zitat Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM (2007) Gene-expression variation within and among human populations. Am J Hum Genet 80:502–509PubMedPubMedCentralCrossRef Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM (2007) Gene-expression variation within and among human populations. Am J Hum Genet 80:502–509PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Zhang W, Dolan ME (2008) Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics 9:489–492PubMedCrossRef Zhang W, Dolan ME (2008) Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics 9:489–492PubMedCrossRef
35.
Zurück zum Zitat Scotting PJ, Walker DA, Perilongo G (2005) Opinion: childhood solid tumours: a developmental disorder. Nat Rev Cancer 5:481–488PubMedCrossRef Scotting PJ, Walker DA, Perilongo G (2005) Opinion: childhood solid tumours: a developmental disorder. Nat Rev Cancer 5:481–488PubMedCrossRef
36.
Zurück zum Zitat Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21(5):774–780PubMedCrossRef Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21(5):774–780PubMedCrossRef
37.
Zurück zum Zitat Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister S (2010) Adult and pediatric Medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28:3054–3060PubMedCrossRef Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister S (2010) Adult and pediatric Medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28:3054–3060PubMedCrossRef
38.
Zurück zum Zitat Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, Al-Halabi H, Albrecht S, Jabado N, Eberhart CG, Grajkowska W, Weiss WA, Clifford SC, Bouffet E, Rutka JT, Korshunov A, Pfister S, Taylor MD (2011) Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122:231–240PubMedPubMedCentralCrossRef Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, Al-Halabi H, Albrecht S, Jabado N, Eberhart CG, Grajkowska W, Weiss WA, Clifford SC, Bouffet E, Rutka JT, Korshunov A, Pfister S, Taylor MD (2011) Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122:231–240PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068PubMedPubMedCentralCrossRef Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A (2009) Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol 27:3391–3397PubMedCrossRef Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A (2009) Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol 27:3391–3397PubMedCrossRef
41.
Zurück zum Zitat Akagi EM, Lavorato-Rocha AM, Maia B d M, Rodrigues IS, Carvalho KC, Stiepcich MM, Baiocchi G, Sato-Kuwabara Y, Rogatto SR, Soares FA, Rocha RM (2014) ROCK1 as a novel prognostic marker in vulvar cancer. BMC Cancer 14:822PubMedPubMedCentralCrossRef Akagi EM, Lavorato-Rocha AM, Maia B d M, Rodrigues IS, Carvalho KC, Stiepcich MM, Baiocchi G, Sato-Kuwabara Y, Rogatto SR, Soares FA, Rocha RM (2014) ROCK1 as a novel prognostic marker in vulvar cancer. BMC Cancer 14:822PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Amaya CN, Mitchell DC, Bryan BA (2017) Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth. BMC Cancer 17:485PubMedPubMedCentralCrossRef Amaya CN, Mitchell DC, Bryan BA (2017) Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth. BMC Cancer 17:485PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Islam M, Datta J, Lang JC, Teknos TN (2014) Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma. Oral Oncol 50:448–456PubMedPubMedCentralCrossRef Islam M, Datta J, Lang JC, Teknos TN (2014) Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma. Oral Oncol 50:448–456PubMedPubMedCentralCrossRef
Metadaten
Titel
microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma
verfasst von
Gabriela Molinari Roberto
Regia Caroline Lira
Lara Elis Delsin
Gabriela Maciel Vieira
Marcela Oliveira Silva
Rodrigo Guedes Hakime
Mauricio Eiji Yamashita
Edgard Eduard Engel
Carlos Alberto Scrideli
Luiz Gonzaga Tone
María Sol Brassesco
Publikationsdatum
12.03.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00633-0

Weitere Artikel der Ausgabe 2/2020

Pathology & Oncology Research 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.